Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Protalix BioTherapeutics (PLX) FCF Margin (2016 - 2025)

Protalix BioTherapeutics has reported FCF Margin over the past 16 years, most recently at 31.75% for Q4 2025.

  • Quarterly results put FCF Margin at 31.75% for Q4 2025, up 653.0% from a year ago — trailing twelve months through Dec 2025 was 23.44% (down 3921.0% YoY), and the annual figure for FY2025 was 23.44%, down 3921.0%.
  • FCF Margin for Q4 2025 was 31.75% at Protalix BioTherapeutics, up from 23.7% in the prior quarter.
  • Over the last five years, FCF Margin for PLX hit a ceiling of 107.84% in Q1 2024 and a floor of 90.28% in Q1 2021.
  • Median FCF Margin over the past 5 years was 32.1% (2024), compared with a mean of 14.88%.
  • Biggest five-year swings in FCF Margin: skyrocketed 17039bps in 2021 and later plummeted -17936bps in 2022.
  • Protalix BioTherapeutics' FCF Margin stood at 48.78% in 2021, then soared by 33bps to 32.77% in 2022, then surged by 197bps to 31.9% in 2023, then dropped by -21bps to 25.22% in 2024, then grew by 26bps to 31.75% in 2025.
  • The last three reported values for FCF Margin were 31.75% (Q4 2025), 23.7% (Q3 2025), and 36.17% (Q2 2025) per Business Quant data.